Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial
10.1200/JCO.2011.39.9824
Saved in:
Main Authors: | Van Cutsem, E., De Haas, S., Kang, Y.-K., Ohtsu, A., Tebbutt, N.C., Xu, J.M., Yong, W.P., Langer, B., Delmar, P., Scherer, S.J., Shah, M.A. |
---|---|
Other Authors: | CANCER SCIENCE INSTITUTE OF SINGAPORE |
Format: | Article |
Published: |
2014
|
Online Access: | http://scholarbank.nus.edu.sg/handle/10635/116937 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | National University of Singapore |
Similar Items
-
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients
by: D. A. Reardon, et al.
Published: (2018) -
Identification of gastric cancer biomarkers using 1H nuclear magnetic resonance spectrometry
by: Ramachandran G.K., et al.
Published: (2018) -
Bevacizumab for retinopathy of prematurit
by: Lim, L.S., et al.
Published: (2014) -
Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): A phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum
by: Glynne-Jones, R, et al.
Published: (2020) -
Intraperitoneal chemotherapy for gastric cancer with peritoneal disease: experience from Singapore and Japan
by: Kono K., et al.
Published: (2018)